Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday

Upstream Bio (NASDAQ:UPB) is expected to post its Q4 2025 results before the market opens on Wednesday, March 11th. Analysts expect the company to announce earnings of ($0.73) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 12, 2026 at 12:30 PM ET.

Upstream Bio Price Performance

Shares of NASDAQ UPB opened at $7.36 on Wednesday. Upstream Bio has a 1-year low of $5.14 and a 1-year high of $33.68. The business has a fifty day moving average price of $23.29 and a 200 day moving average price of $22.56. The stock has a market capitalization of $397.73 million, a P/E ratio of -3.91 and a beta of 2.96.

Analyst Ratings Changes

Several analysts have commented on UPB shares. Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th. Lifesci Capital assumed coverage on shares of Upstream Bio in a research note on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, January 21st. Finally, Evercore began coverage on shares of Upstream Bio in a report on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $45.25.

Institutional Investors Weigh In On Upstream Bio

A number of institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. increased its holdings in Upstream Bio by 6.4% in the 2nd quarter. Invesco Ltd. now owns 16,300 shares of the company’s stock worth $179,000 after buying an additional 985 shares during the period. JPMorgan Chase & Co. lifted its stake in Upstream Bio by 8.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock valued at $181,000 after acquiring an additional 1,275 shares during the period. Legal & General Group Plc boosted its holdings in shares of Upstream Bio by 83.0% in the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after acquiring an additional 1,440 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Upstream Bio in the fourth quarter worth $45,000. Finally, BNP Paribas Financial Markets increased its stake in shares of Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after acquiring an additional 2,158 shares during the period.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.